Search
Hydroxyproline
go.drugbank.com/drugs/DB08847ApprovedTherapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds. … It is found in collagen and as such it is common in many gelatin products. Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis.
Nedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigational[A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalCurrently under investigation for use in psychotic depression (phase 3 trials). … As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.
Albumin Aggregated
go.drugbank.com/drugs/DB14230ApprovedAlbumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection.
Fluocinolone acetonide
go.drugbank.com/drugs/DB00591ApprovedInvestigationalVet approved[T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices. … [T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]
Mixtures: OCIDERM-N, CINOLON-NCortisone acetate
go.drugbank.com/drugs/DB01380ApprovedInvestigationalCortisone acetate was first isolate in 1935 and became more widely researched in 1949. … [A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.
Ethanolamine oleate
go.drugbank.com/drugs/DB06689ApprovedEthanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.
Categories: Compounds used in a research, industrial, or household settingCefepime
go.drugbank.com/drugs/DB01413ApprovedInvestigationalCefepime is a fourth-generation cephalosporin antibiotic developed in 1994. … [A249050] The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the
Synonyms: (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylateVoxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalwith an HCV regimen containing sofosbuvir without an NS5A inhibitor [L935]. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated